Merrimack expands Phase 3 NAPOLI-1 study
MM-398 is designed to optimise the delivery of irinotecan by extending the duration of circulation in the body and preferentially activating the drug within the tumour to achieve
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.
Voclosporin is a new generation calcineurin inhibitor licensed from Isotechnika Pharma. According to the approved protocol, the study will be a Phase III, randomized, multi-center, concentration-controlled comparison study